Launch of Solution to Predict Preclinical Toxicity ...
November 17 2015 - 2:00AM
UK Regulatory
/**/
RNS Number : 8845F
Cyprotex PLC
17 November 2015
Cyprotex PLC
("Cyprotex" or "the
Company")
Launch of New Solution to Predict Preclinical
Toxicity
17th November
2015;
Cyprotex PLC (AIM:CRX), a specialist Contract
Research Organisation (CRO), announced today the launch of its new
in silico modelling
solution, chemTox, which predicts genotoxicity and rat
LD50 directly from chemical structure. The
LD50 is a commonly determined parameter in preclinical
toxicity studies, representing the dose that causes death in 50% of
the test group. Using models such as those in chemTox to predict
this parameter will have obvious ethical benefits in reducing
animal toxicity testing.
chemTox has been developed by Cyprotex's Scientific
Computing Group using quantitative structure property relationship
(QSPR) modelling, a technique that relates calculable chemical
characteristics of a molecule to important properties such as its
toxicity. As chemTox requires no experimental data inputs it can be
used as a virtual screening tool prior to chemical synthesis. There
are significant cost benefits to this approach as chemTox can be
applied as an early stage filter for directing chemistry and
prioritising subsequent in
vitro screening by taking into account the predicted safety
of the molecule. Cyprotex not only provide the in silico predictions but can provide a
full tiered screening strategy with safety of the molecules
substantiated using a panel of in
vitro toxicity assays.
By utilising chemTox alongside complementary virtual
screening tools such as chemPKTM, which was launched by
Cyprotex in July, it is possible to predict both preclinical safety
and human exposure in combination. Both systems operate on a
similar KNIME workflow management platform which allows further
integration with many other cheminformatics, analytics and
modelling tools.
Dr Anthony Baxter, Cyprotex's Chief Executive
Officer, comments: 'The ethical concerns over animal testing are
intensifying and new approaches which reduce or in the future
replace animal safety testing are a key focus. Virtual screening
tools such as chemTox address this need, and are becoming widely
used in industries such as cosmetics and personal care where a
complete ban on animal testing has been enforced.'
For further information:
Cyprotex PLC
|
Tel: +44 (0) 1625 505 100
|
Dr Anthony Baxter, Chief Executive
Officer
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
|
ir@cyprotex.com
www.cyprotex.com
|
|
|
N+1 Singer (Nomad and broker
to Cyprotex)
|
Tel: +44 (0)20 7496 3000
|
Shaun Dobson
Jen Boorer
|
shaun.dobson@n1singer.com
jennifer.boorer@n1singer.com
www.n1singer.com
|
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market
of the London Stock Exchange (CRX). It has sites at Macclesfield
and Alderley Park, both of which are near Manchester in the UK, and
at Watertown, MA and Kalamazoo, MI in the US. The Company was
established in 1999 and works with more than 1300 partners within
the pharmaceutical and biotech industry, cosmetics and personal
care industry and the chemical industry. Cyprotex acquired Apredica
and the assets of Cellumen Inc. in August 2010 and the combined
business provides support for a wide range of experimental and
computational ADME-Tox and PK services. The acquisition of the
assets and business of CeeTox in January 2014 has enabled Cyprotex
to expand its range of services to target the personal care,
cosmetics and chemical industries. In 2015, Cyprotex launched its
new bioscience division to expand its capabilities into phenotypic
and target based screening. The Company's core capabilities include
high quality in vitro ADME
screening services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr® toxicity prediction technology, bioscience
services, predictive modelling solutions, including
Cloe® PK, chemPKTM and chemTox, and a range
of skin, ocular and endocrine disruption services. For more
information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the
London Stock Exchange
END
NRAPKADNPBDDDDD
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024